Filing identity and reporting period
Important mismatch: The supplied filing is a Form 10-Q for DelMar Pharmaceuticals, Inc., not Tuhura Biosciences, Inc. It covers the quarter and six months ended December 31, 2016 (DelMar’s fiscal second quarter and first half of fiscal 2017). The interim financial statements are unaudited and reported in U.S. dollars.
Business context
DelMar describes itself as a clinical-stage cancer drug developer. Its lead candidate, VAL-083, was being studied for glioblastoma (GBM); the company also held certain exclusive commercial rights in China, where VAL-083 was approved for chronic myelogenous leukemia and lung cancer. The company reported no revenue to date.
Key financial metrics
| Metric | Three months ended Dec. 31, 2016 | Six months ended Dec. 31, 2016 | Comparator / balance |
|---|---|---|---|
| Revenue | None reported | None reported | No revenue to date |
| Research and development expense | $1.121 million | $1.854 million | Prior-year periods: $0.789 million and $1.393 million |
| General and administrative expense | $0.571 million | $1.888 million | Prior-year periods: $0.891 million and $1.365 million |
| Net loss | $1.322 million | $3.612 million | Prior-year periods: $2.647 million and $4.268 million |
| Loss per share | $0.13 | $0.36 | Prior-year periods: $0.24 and $0.40 |
| Cash used in operating activities | Not separately stated | $3.062 million | Prior-year six-month cash use: $2.635 million |
| Cash and cash equivalents | $3.417 million at Dec. 31, 2016 | $6.157 million at June 30, 2016 | |
| Working capital | $2.845 million at Dec. 31, 2016 | $5.692 million at June 30, 2016 | |
| Total assets / total liabilities | $3.594 million / $0.892 million at Dec. 31, 2016 | No material conventional borrowings are reported |
Operating margins are not meaningful because the company had no revenue. Cash fell by $2.740 million over the six months. Current liabilities included $0.516 million of accounts payable and accrued liabilities and $0.205 million of related-party payables.
Changes versus prior comparable periods
- Quarterly net loss improved from $2.647 million to $1.322 million; six-month net loss improved from $4.268 million to $3.612 million. The company attributed substantial earnings volatility to noncash fair-value changes in warrant and option liabilities; the six-month period included a $0.136 million fair-value gain versus a $1.220 million loss in the prior year.
- Quarterly R&D expense rose 42%, and six-month R&D rose 33%, primarily with clinical-trial preparation, manufacturing, intellectual-property work, preclinical research, and personnel.
- Quarterly G&A expense declined 36%, but six-month G&A increased 38%, reflecting professional, listing, facilities, personnel, and noncash costs.
- Six-month operating cash use increased from $2.635 million to $3.062 million, while financing cash inflows fell from $2.855 million to $0.323 million. Current-period financing inflows were from warrant exercises; no new offering proceeds were reported for the six months.
Outlook, risks, and unusual items
- Funding and going concern: Management estimated that cash on hand, together with reported resources, would fund planned operations through the end of calendar 2017. The filing also says additional funding will be needed in the near future, identifies material uncertainty that may cast substantial doubt on the company’s ability to continue as a going concern, and notes that financing plans are not assured. Management was pursuing new equity and/or strategic partnerships.
- Development plans: DelMar planned a randomized pivotal Phase III study of VAL-083 in bevacizumab-refractory GBM, subject to FDA guidance and funding. It reported initiating a Phase II study with MD Anderson in January 2017. The filing describes these programs as plans or ongoing development, not established regulatory outcomes.
- Clinical evidence and safety: Management highlighted Phase I/II data, including median survival of 8.35 months after bevacizumab failure in a small, non-controlled subgroup. The filing cautions that the data are limited; thrombocytopenia and other blood-count toxicities were observed.
- Potential dilution and obligations: Series B preferred shares carried a 9% cumulative dividend payable in common shares and a low-single-digit royalty arrangement on future product sales. The filing also reports outstanding warrants, options, and convertible preferred stock. Subsequent to quarter-end, a related-party entity exercised 125,000 warrants for $192,075.
- Controls: Management concluded disclosure controls and procedures were not effective at period-end because of a material weakness previously reported in the 2016 Form 10-K. No material changes to internal control were reported during the quarter.
- Other items: The company recorded a $0.467 million Series B stock dividend for the six months and amended certain options, reclassifying $0.261 million from liability to equity. No legal proceedings were reported.
Most important facts to verify
- Confirm the intended issuer: the supplied filing names DelMar Pharmaceuticals, Inc., not Tuhura Biosciences, Inc.
- Confirm the intended reporting period: this filing is for the quarter ended December 31, 2016, not a calendar-year second quarter.
- Assess cash runway and the feasibility, timing, and terms of additional financing; the stated end-of-2017 runway is management’s estimate.
- Check the status, funding requirements, and regulatory path for the planned Phase III program and other clinical studies.
- Review the previously identified material weakness and subsequent remediation disclosures, as well as potential dilution and preferred-share royalty/dividend obligations.